Open Access
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases
Scott J. Hecker
1
,
K.Raja Reddy
1
,
Olga Lomovskaya
1
,
David C Griffith
1
,
Debora Rubio Aparicio
1
,
KIRK NELSON
1
,
Ruslan Tsivkovski
1
,
Dongxu Sun
1
,
Mojgan Sabet
1
,
Ziad Tarazi
1
,
Jonathan Parkinson
1
,
Maxim Totrov
2
,
Serge H Boyer
1
,
Tomasz W. Glinka
1
,
Orville A Pemberton
3
,
Yu Chen
3
,
Michael N. Dudley
1
1
Qpex Biopharma, Inc., 6275 Nancy Ridge Drive, Suite 100, San Diego, California 92121, United States
|
2
Molsoft LLC, 11199 Sorrento Valley Road, San Diego, California 92121, United States
|
Publication type: Journal Article
Publication date: 2020-03-09
scimago Q1
wos Q1
SJR: 1.801
CiteScore: 11.5
Impact factor: 6.8
ISSN: 00222623, 15204804
PubMed ID:
32150407
Drug Discovery
Molecular Medicine
Abstract
Despite major advances in the beta-lactamase inhibitor field, certain enzymes remain refractory to inhibition by agents recently introduced. Most important among these are the Class B (metallo) enzyme NDM-1 of Enterobacteriaceae and the Class D (OXA) enzymes of Acinetobacter baumannii. Continuing the boronic acid program that led to vaborbactam, efforts were directed toward expanding the spectrum to allow treatment of a wider range of organisms. Through key structural modifications of a bicyclic lead, stepwise gains in spectrum of inhibition were achieved, ultimately resulting in QPX7728 (35). This compound displays a remarkably broad spectrum of inhibition, including Class B and Class D enzymes, and is little affected by porin modifications and efflux. Compound 35 is a promising agent for use in combination with a beta-lactam antibiotic for the treatment of a wide range of multidrug resistant gram-negative bacterial infections, by both intravenous and oral administration.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
|
|
|
Antimicrobial Agents and Chemotherapy
20 publications, 10.81%
|
|
|
Journal of Medicinal Chemistry
16 publications, 8.65%
|
|
|
European Journal of Medicinal Chemistry
12 publications, 6.49%
|
|
|
Antibiotics
7 publications, 3.78%
|
|
|
ACS Infectious Diseases
6 publications, 3.24%
|
|
|
Molecules
4 publications, 2.16%
|
|
|
International Journal of Molecular Sciences
4 publications, 2.16%
|
|
|
Biomolecules
4 publications, 2.16%
|
|
|
Bioorganic and Medicinal Chemistry
4 publications, 2.16%
|
|
|
Angewandte Chemie - International Edition
4 publications, 2.16%
|
|
|
Angewandte Chemie
4 publications, 2.16%
|
|
|
RSC Medicinal Chemistry
4 publications, 2.16%
|
|
|
Current Opinion in Infectious Diseases
2 publications, 1.08%
|
|
|
Pharmaceuticals
2 publications, 1.08%
|
|
|
Frontiers in Microbiology
2 publications, 1.08%
|
|
|
Organic Letters
2 publications, 1.08%
|
|
|
Bioorganic and Medicinal Chemistry Letters
2 publications, 1.08%
|
|
|
Chemistry - A European Journal
2 publications, 1.08%
|
|
|
ChemMedChem
2 publications, 1.08%
|
|
|
Chemical Reviews
2 publications, 1.08%
|
|
|
Expert Opinion on Therapeutic Patents
2 publications, 1.08%
|
|
|
Chemical Communications
2 publications, 1.08%
|
|
|
International Journal of Biological Macromolecules
2 publications, 1.08%
|
|
|
International Journal of Antimicrobial Agents
2 publications, 1.08%
|
|
|
Microorganisms
2 publications, 1.08%
|
|
|
Expert Review of Anti-Infective Therapy
2 publications, 1.08%
|
|
|
Microbiology spectrum
2 publications, 1.08%
|
|
|
Journal of Enzyme Inhibition and Medicinal Chemistry
2 publications, 1.08%
|
|
|
Chemical Science
2 publications, 1.08%
|
|
|
5
10
15
20
|
Publishers
|
5
10
15
20
25
30
35
40
45
|
|
|
Elsevier
41 publications, 22.16%
|
|
|
American Chemical Society (ACS)
33 publications, 17.84%
|
|
|
MDPI
25 publications, 13.51%
|
|
|
American Society for Microbiology
23 publications, 12.43%
|
|
|
Wiley
16 publications, 8.65%
|
|
|
Springer Nature
13 publications, 7.03%
|
|
|
Royal Society of Chemistry (RSC)
9 publications, 4.86%
|
|
|
Taylor & Francis
8 publications, 4.32%
|
|
|
Frontiers Media S.A.
5 publications, 2.7%
|
|
|
Georg Thieme Verlag KG
3 publications, 1.62%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.08%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 1.08%
|
|
|
Han-Gug Misaengmul Hag-hoe/The Microbiological Society of Korea
1 publication, 0.54%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.54%
|
|
|
Oxford University Press
1 publication, 0.54%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.54%
|
|
|
5
10
15
20
25
30
35
40
45
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
185
Total citations:
185
Citations from 2024:
69
(37%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Hecker S. J. et al. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases // Journal of Medicinal Chemistry. 2020. Vol. 63. No. 14. pp. 7491-7507.
GOST all authors (up to 50)
Copy
Hecker S. J., Reddy K., Lomovskaya O., Griffith D. C., Rubio Aparicio D., NELSON K., Tsivkovski R., Sun D., Sabet M., Tarazi Z., Parkinson J., Totrov M., Boyer S. H., Glinka T. W., Pemberton O. A., Chen Yu., Dudley M. N. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases // Journal of Medicinal Chemistry. 2020. Vol. 63. No. 14. pp. 7491-7507.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1021/acs.jmedchem.9b01976
UR - https://doi.org/10.1021/acs.jmedchem.9b01976
TI - Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases
T2 - Journal of Medicinal Chemistry
AU - Hecker, Scott J.
AU - Reddy, K.Raja
AU - Lomovskaya, Olga
AU - Griffith, David C
AU - Rubio Aparicio, Debora
AU - NELSON, KIRK
AU - Tsivkovski, Ruslan
AU - Sun, Dongxu
AU - Sabet, Mojgan
AU - Tarazi, Ziad
AU - Parkinson, Jonathan
AU - Totrov, Maxim
AU - Boyer, Serge H
AU - Glinka, Tomasz W.
AU - Pemberton, Orville A
AU - Chen, Yu
AU - Dudley, Michael N.
PY - 2020
DA - 2020/03/09
PB - American Chemical Society (ACS)
SP - 7491-7507
IS - 14
VL - 63
PMID - 32150407
SN - 0022-2623
SN - 1520-4804
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Hecker,
author = {Scott J. Hecker and K.Raja Reddy and Olga Lomovskaya and David C Griffith and Debora Rubio Aparicio and KIRK NELSON and Ruslan Tsivkovski and Dongxu Sun and Mojgan Sabet and Ziad Tarazi and Jonathan Parkinson and Maxim Totrov and Serge H Boyer and Tomasz W. Glinka and Orville A Pemberton and Yu Chen and Michael N. Dudley},
title = {Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases},
journal = {Journal of Medicinal Chemistry},
year = {2020},
volume = {63},
publisher = {American Chemical Society (ACS)},
month = {mar},
url = {https://doi.org/10.1021/acs.jmedchem.9b01976},
number = {14},
pages = {7491--7507},
doi = {10.1021/acs.jmedchem.9b01976}
}
Cite this
MLA
Copy
Hecker, Scott J., et al. “Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.” Journal of Medicinal Chemistry, vol. 63, no. 14, Mar. 2020, pp. 7491-7507. https://doi.org/10.1021/acs.jmedchem.9b01976.
Profiles